MENU
+Compare
ENTA
Stock ticker: NASDAQ
AS OF
Jul 29, 04:59 PM (EDT)
Price
$8.08
Change
+$0.05 (+0.62%)
Capitalization
172.72M

ENTA Enanta Pharmaceuticals Forecast, Technical & Fundamental Analysis

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases... Show more

Industry: #Biotechnology
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ENTA with price predictions
Jul 28, 2025

ENTA in upward trend: price rose above 50-day moving average on July 16, 2025

ENTA moved above its 50-day moving average on July 16, 2025 date and that indicates a change from a downward trend to an upward trend. In of 28 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 23, 2025. You may want to consider a long position or call options on ENTA as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ENTA just turned positive on July 28, 2025. Looking at past instances where ENTA's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ENTA advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .

ENTA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for ENTA moved out of overbought territory on July 03, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 49 cases where ENTA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENTA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ENTA entered a downward trend on July 18, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ENTA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.847) is normal, around the industry mean (18.071). P/E Ratio (0.000) is within average values for comparable stocks, (60.048). ENTA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.620). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (2.662) is also within normal values, averaging (281.754).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ENTA is expected to report earnings to fall 20.73% to -84 cents per share on August 11

Enanta Pharmaceuticals ENTA Stock Earnings Reports
Q2'25
Est.
$-0.84
Q1'25
Beat
by $0.10
Q4'24
Beat
by $0.22
Q3'24
Missed
by $0.20
Q2'24
Beat
by $0.36
The last earnings report on May 12 showed earnings per share of -105 cents, beating the estimate of -115 cents. With 59.81K shares outstanding, the current market capitalization sits at 172.72M.
A.I. Advisor
published General Information

General Information

a developer of drugs and other pharmaceuticals products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
500 Arsenal Street
Phone
+1 617 607-0800
Employees
145
Web
https://www.enanta.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PHJMF0.050.01
+18.76%
PT Hanjaya Mandala Sampoerna Terbuka
CBWA12.10N/A
N/A
Commencement Bancorp Inc
DNSKF35.00N/A
N/A
Danske Bank A/S
FCRM0.04N/A
N/A
Franklin Credit Management Corp.
PLRRF6.40N/A
N/A
Polar Capital Holdings PLC

ENTA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with ALEC. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then ALEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
+8.51%
ALEC - ENTA
41%
Loosely correlated
N/A
BEAM - ENTA
41%
Loosely correlated
-4.10%
SCPH - ENTA
40%
Loosely correlated
-3.39%
PRME - ENTA
38%
Loosely correlated
-2.85%
KRYS - ENTA
37%
Loosely correlated
+3.59%
More